Who Paid My Doc
George Cornett
Internal Medicine Franklin, IN Medical Doctor
NPI 1902808199 CMS profile 176395
990 E State Road 44, Franklin, IN 46131
General payments
$4,325
Research payments
$75,868
Ownership & investment interest
$0
Research they led as principal investigator
$1,333,104
Through program year 2025, George Cornett of Franklin, IN is reported in the CMS Open Payments database as having received $4,325 across 100 general payments and $75,868 in research payments paid to them. Separately, studies naming them as principal investigator received $1,333,104 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $108 | 6 | |
| 2024 | General | $2,319 | 20 | |
| 2024 | Research | $38,240 | 2 | |
| 2023 | General | $969 | 10 | |
| 2023 | Research | $858 | 2 | |
| 2022 | General | $100 | 6 | |
| 2022 | Research | $447 | 1 | |
| 2021 | Research | $34,585 | 2 | |
| 2020 | General | $128 | 10 | |
| 2020 | Research | $1,738 | 19 | |
| 2019 | General | $701 | 48 |
Beside peers
- George Cornett
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to George Cornett were reported at $108. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | George Cornett | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $701 | $159 | $48–$570 | $163 |
| 2020 | $128 | $119 | $33–$402 | $114 |
| 2021 | $0 | $135 | $37–$521 | $132 |
| 2022 | $100 | $141 | $42–$496 | $149 |
| 2023 | $969 | $149 | $45–$519 | $160 |
| 2024 | $2,319 | $154 | $47–$537 | $164 |
| 2025 | $108 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 179 drugsPart D claims
11,840
Drug cost
$1,060,924
Branded share of claims
22.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 166 | $181,846 | |
| Mounjaro Tirzepatide | Brand | 144 | $164,167 | |
| Eliquis Apixaban | Brand | 123 | $112,312 | |
| Januvia Sitagliptin Phosphate | Brand | 68 | $88,553 | |
| Ozempic Semaglutide | Brand | 83 | $84,774 | |
| Trulicity Dulaglutide | Brand | 69 | $83,167 | |
| Rybelsus Semaglutide | Brand | 24 | $36,910 | |
| Xarelto Rivaroxaban | Brand | 35 | $27,942 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 47 | $26,694 | |
| Farxiga Dapagliflozin Propanediol | Brand | 33 | $24,641 |
The 10 drugs with the highest cost, of 179 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 78 billing codesPaid by Medicare
$125,878
Medicare patients
368
Services billed
2,808
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 39% | |
| Diabetes | 36% | |
| Chronic kidney disease | 35% | |
| Ischemic heart disease | 34% | |
| Heart failure | 25% | |
| Depression | 23% | |
| Atrial fibrillation | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90653 | Office | 105 | 105 | $8,591 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
126 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Indiana
Abhinav Singh
Internal Medicine · Greenwood, IN
Girish Kunapareddy
Internal Medicine · Terre Haute, IN
Raj Vuppalanchi
Internal Medicine · Indianapolis, IN
Joseph Arulandu
Internal Medicine · La Porte, IN
Napoleon Maminta
Internal Medicine · Indianapolis, IN
Jennifer Paisley
Internal Medicine · Lawrenceburg, IN
Related records
Internal Medicine in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.